Twenty-three patients received some kind of salvage treatment. In more detail, 14 patients underwent re-irradiation, 15 patients received ChT for recurrent disease and 14 patients underwent surgery for recurrent disease. Patients treated for their recurrent disease had a significantly longer survival compared to patients who underwent best supportive care (BSC) at progression of their disease (mOS 8.8 vs. 22.3 months, p < 0.001).